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Update on HDFN:
new information on long-standing
controversies
A.F. EDER
Hemolytic disease of the fetus and newborn (HDFN) results from
maternal IgG antibodies that cross the placenta to the fetal
circulation during gestation and cause RBC destruction and
complications before birth (HDF), or anemia and
hyperbilirubinemia after birth (HDN), or both. In its most severe
form,HDF produces hydrops fetalis,which is characterized by total
body edema, hepatosplenomegaly, and heart failure and can lead to
intrauterine death. Before discovery of Rh immunoglobulin (RhIG),
HDFN from anti-D was a significant cause of perinatal mortality or
long-term disability. Routine administration of RhIG to D– women
during pregnancy and shortly after the birth of D+ infants
effectively reduced the incidence of HDFN caused by anti-D.
Maternal alloimmunization to other RBC antigens in the Rh, Kell,
and other blood group systems can not be routinely prevented and
these antibodies can also cause HDFN. Advances in prenatal care,
noninvasive monitoring, and intrauterine transfusion have
improved the outlook for affected pregnancies to the extent that
even hydrops fetalis can be reversed and effectively treated in many
cases. This review will provide an update on the current issues in
prevention and treatment of HDFN, emphasizing recent insights
into long-standing controversies regarding maternal weak D
phenotypes and D alloimmunization, noninvasive fetal diagnosis
and monitoring of affected pregnancies, and recent treatment
guidelines. Immunohematology 2006;22:188–195.
The incidence of D alloimmunization in pregnancy
decreased from 14 percent to between 1 and 2 percent
following the introduction of postnatal prophylaxis
with Rh immunoglobulin (RhIG) in the late 1960s and,
after 1979,was further reduced to 0.1 percent with the
addition of routine antenatal RhIG prophylaxis.1–3
Smaller family size in recent decades has also
contributed to the decline in the number of cases, but
hemolytic disease of the fetus and newborn (HDFN)
caused by anti-D continues to occur in about 6.7 of
1000 live births in the United States, which likely
reflects inadvertent failure to administer RhIG
prophylaxis, inadequate prenatal care, or antenatal
sensitization prior to RhIG administration at 28 weeks’
gestation.4,5
More than 50 different specificities of RBC
antibodies have been implicated in HDFN, but most
cases of severe fetal anemia that require treatment in
utero are caused by anti-D or anti-c (Rh system),or anti-
K (Kell system) (Table 1).1,2,6 The epidemiology of
HDFN in different ethnic and racial populations
directly reflects the frequency of blood group alleles in
the population and the likelihood of incompatibility
and consequent maternal alloimmunization.6,7
Incompatibility with respect to the D antigen occurs in
about 10 percent of all pregnancies among Caucasians
and African Americans; in contrast, the D– phenotype is
extremely rare among Asian women and HDFN caused
by anti-D is seldom encountered in these populations.
In a study of 17,568 screened pregnancies, the
prevalence of new antibody production was 0.24
percent (95% CI, 0.17–0.32).8 Anti-D is still one of the
most common antibodies found in pregnant women,
but other antibodies have surpassed anti-D in some
studies. In one large series, anti-K was detected at a rate
of 3.2 per 1000 maternal samples compared with anti-
D at 2.6 per 1000.9 In another recent study of 1133
Dutch women with positive antibody screens, anti-E
was the most common antibody detected (23%)
followed by anti-K (18.8%), anti-D (18.7%), and anti-c
(10.4%).10
Severe hemolytic disease requiring intrauterine
transfusion was caused by anti-D, -K, or -c, in 85
percent, 10 percent, and 3.5 percent of HDF cases,
respectively.11 Rh and Kell antibodies are more likely
associated with severe hemolysis than are other
antibodies, but HDFN associated with these and other
blood group antibodies can demonstrate a broad
spectrum of symptoms, ranging from mild anemia and
hyperbilirubinemia in an infant to life-threatening
complications before birth. About one-half of D+
infants with detectable maternal anti-D in their serum
are unaffected or only mildly affected and require no
treatment; whereas 20 percent are severely affected in
utero.1,2 About one-half of these severely affected
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fetuses have significant hemolysis before 34 weeks’
gestation and require intrauterine transfusion. A similar
spectrum of disease severity is observed with anti-c,
anti-K, and anti-Fya, with severe disease affecting as
many as 7 percent, 38 percent, and 16 percent of
susceptible fetuses, respectively.1,2 Subsequent
pregnancies are more likely to be severely affected
than are first pregnancies because of the anamnestic
immune response.
Weak D and RhIG Prophylaxis
To prevent maternal alloimmunization, RhIG
should be given to all D– women who do not have
detectable anti-D at 28 weeks’ gestation and within 72
hours of delivery or other potentially sensitizing
event.12 Testing for ABO,D, and unexpected antibodies
should be performed on samples from all pregnant
women in the first trimester, but the need to test D–
pregnant women for weak expression of D has been
controversial.13,14 Considerable variability in practice
exists within the United States even though such
testing is not required by AABB or the American
College of Obstetricians and Gynecologists (ACOG).12,13
The majority (90%) of individuals with a weak D
phenotype are weak D type 1, 2, or 3 and express
normal, but reduced, quantities of D antigens on the
RBC surface; these individuals cannot be immunized to
make anti-D. The remaining 10 percent of individuals
with a weakened expression of D express aberrant D
proteins and may not be recognized as having a partial
D phenotype until they develop anti-D. Most Caucasian
D+ individuals with anti-D belong to partial D category
DVI which occurs in 0.02 percent to 0.05 percent of
Caucasians.14 Alloimmunization to the D antigen and
HDFN caused by anti-D can occur in women with
partial D antigen expression.15,16 Denomme et al.15
evaluated partial D, weak D types, and novel RHD
alleles among 33,864 screened multiethnic patients
and found 54 typing discrepancies which represented
mutated RHD alleles. Among these cases, 10 of 25
(35%) obstetric patients were assigned D+ status, but
expressed a D variant known to permit anti-D
alloimmunization (e.g., DAR, DFR, and DAU, and
categories DIIIa, DVa, and DVI).
The frequency with which partial D individuals
develop anti-D in the general population is not known,
but it may be higher than previously recognized, as
demonstrated in a recent CAP survey that found that
one-third of transfusion services reported at least one
patient whose RBCs were of a weak D phenotype with
anti-D formation in a 12-month period.17 Although
severe HDF in women whose RBCs are of a weak D
phenotype is rare, antibodies have been more
frequently reported in women with a partial DVI
phenotype, and fatal HDF has occurred in pregnancies
of such alloimmunized women.16
AABB does not require testing for weak D in
pregnancy,and, if an IAT is not performed,most women
with partial D will be classified as D– and will be
candidates for RhIG. In the CAP survey, however, 58.2
percent of transfusion services routinely performed
testing for weak D in patients whose RBCs were
negative in direct testing with anti-D reagents.17 AABB
Standards require designating the RBCs of individuals
with positive tests for weak D as D+, and the ACOG
advises against administering RhIG to women with
Table 1. Probability of causing severe HDFN associated with RBC antibodies2,36 *
Highest likelihood Usually associated
Blood group of severe HDFN Rare cases of severe HDFN with mild disease Not a cause of HDFN
MNS M, S, s, U,Mia,Vw,Mur,Mta, Hut, Hil, Mv, M, S, s, U,Mta, Mit N
Far, sD, Ena, MUT
Rh D, c C, E, f, Ce, Cw, Cx, Ew, G, Hr0, Hr, Rh29, E, e, f, C
x, Dw, Rh29, Riv,
Goa, Rh32, Bea, Evans,Tar, Rh42, Sec, LOCR
JAL, STEM
Lutheran Lua (rare), Lub
Kell K k, Kpa, Kpb, Ku, Jsa, Jsb, Ula, K11, K22 Ku, Jsa, K11 K23, K24
Lewis Lea, Leb
Duffy Fya Fyb (rare), Fy3 (rare)
Kidd Jka Jkb (rare), Jk3
Other Dia,Wra, Rd, Coa, Co3, PP1Pk Dib, Sc3, Cob, Ge2 (rare), P1,Wrb,Yta,Ytb, Sc1, Sc2, CH/RG,
Vel,MAM Ge3, Lsa CROM,KN, JMH, I
Bi, Kg, JONES, HJK, REIT Lan,Ata, Jra Jra
JFV, HOFM HLA: Bga, Bgb, Bgc
* For some of the antibodies listed, the information is based on a very small number of examples, sometimes only one, resulting in overlap between categories.
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RBCs of known weak D phenotypes.12,18 However, the
CAP survey found that only 50 percent of transfusion
services reported weak D as D positive, and 71.1
percent of transfusion services that routinely test for
weak D give RhIG to these pregnant women.17
On the basis of the demonstrated risk of D
alloimmunization in women with a partial D
phenotype, some experts have cautioned that if
pregnant women are tested for weak D, an appropriate
anti-D reagent or technique should be used that will
not detect DVI so that these women are assigned D–
status for transfusion and Rh prophylaxis.14–16 The
alternative is to not test pregnant women (or
transfusion recipients) for weak D,which would result
in most of these individuals being classified as D– and
candidates for RhIG prophylaxis. This presents a
challenge to countries that do not have a sufficient
supply of RhIG and need to more accurately
distinguish those individuals with D variants who are
not at risk of anti-D alloimmunization from those who
are at risk and should receive RhIG prophylaxis. Not
surprisingly, a recent survey showed that international
practices on testing for weak D and RhIG
administration diverge from practice in the United
States, and 8 of 10 countries perform further testing for
weak D or D variants if the woman’s RBCs type as D–
or if the typing results are anomalous, to limit
administration of RhIG to women with partial D at risk
for developing anti-D.19 The relative effectiveness of
RhIG in preventing the sensitization of partial D
women compared with D– women is not yet known.
Infants born to D– women should have their blood
type determined using a reagent and a method that
detects DVI and weak D, and RhIG should be
administered to the mother if the infant’s RBCs type as
D+ (including weak D) within 72 hours of the
delivery.12,13 In addition, routine screening for
fetomaternal hemorrhage (FMH) should be performed
after a D– woman delivers a D+ infant to identify
bleeding in excess of 15 mL of RBCs (30 mL whole
blood), an event that would require administration of
additional postpartum RhIG.12 If the woman’s RBCs are
of a weak D phenotype, the rosette test may yield a
diffusely positive result, and Kleihauer-Betke or other
method may be needed to determine the extent of
FMH.12 Significant (> 30 mL whole blood) FMH
complicates less than 1 percent of deliveries and is
more likely following Cesarean sections or operative
vaginal deliveries, but can occur following uncompli-
cated vaginal deliveries as well.20,21
Noninvasive Fetal Rh Genotyping
The initial type and antibody screen that is
performed for all pregnant women not only identifies
D– women who are candidates for RhIG, but also
identifies alloimmunized women that require further
monitoring for HDF during the pregnancy. If a
clinically significant maternal antibody is present, the
blood type of the biologic father should be determined
to assess whether the antigen could be present on the
RBCs of the fetus. Paternity must be certain, however,
to draw meaningful conclusions. Serologic studies of
RBC antigen expression may be informative. If the
biologic father’s RBCs lack the antigen, the infant is not
at risk for HDF during pregnancy and no further fetal
testing is necessary. If the father’s RBCs have double-
dose expression of the implicated antigen, the trait will
be inherited and the fetus should be monitored for
HDF; if they have single-dose expression, his offspring
have a 50 percent chance of inheriting the blood group
antigen allele. Because no antithetic allele for D exists,
paternal zygosity cannot be definitively predicted by
serologic means. The most probable combination of
haplotypes can be predicted,because RHD inheritance
is closely linked to RHCE, and the probability that the
father is heterozygous for the D allele can be estimated
from a model that takes into account the serologic
results as well as the ethnic background and the
number of previous D+ children.7 Tables of gene
frequencies in Caucasians, African Americans, and
Mexican Americans have been published to estimate
the likelihood of paternal heterozygosity for the D
allele.7,22
If paternal testing indicates that the father may
carry an antigen to which a clinically significant
antibody could be made, fetal testing should be
performed to determine if the allele is present. Most
RBC polymorphisms can now be tested for by
molecular analysis at the DNA level, including the
complex RHD and RHCE loci (for D, C, c, E, and e
antigens), as well as the Kell (for K and k antigens),
Duffy (for Fya and Fyb antigens), and Kidd (for Jka and
Jkb antigens) loci.2 The Rh system is by far the most
complex of the human blood group systems, and
considerable genetic diversity underlies the aberrant
RH alleles associated with the D– phenotype.10,23,24 The
most prevalent D– genotype in Caucasian populations
is the complete deletion of RHD; in African blacks and
African Americans, other variant RHD genes are more
likely to be found.2 The RHD pseudogene, which
contains a 37-bp insertion in exon 4 and results in no
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detectable transcription of the gene, is found in 66
percent of D– black Africans and 24 percent of D–
African Americans.23
Similarly, a variant RHD-CE-D gene encodes the r’s
(dCces) haplotype (phenotype) that underlies serologic
D negativity in 22 percent of D– African Americans.
These variant RHD alleles have important implications
for prenatal diagnosis of fetal blood type in different
populations because the presence of one of these
genes in the fetus can lead to a false positive result (i.e.,
the fetus is predicted to be D+ by molecular methods
but is found to be D– by serology after birth) and
unnecessary prenatal intervention. A maternal blood
sample should be analyzed in parallel with the fetal
sample. False negative results (i.e., the fetus is
predicted to be D– but is found to be D+ by serology
at birth) have been attributed to erroneous paternity or
rearrangement at the paternal RHD gene locus. If no
paternal sample is available, a predicted D– fetal blood
type determined by molecular methods should be
treated with caution, and the pregnancy should be
monitored to ensure that the titer of maternal anti-D
does not increase.2
The most common method to obtain fetal DNA for
molecular testing is still amniocentesis in the United
States because noninvasive alternatives are not yet
available. Amniocentesis is performed at 24 weeks’
gestation and is relatively safe but is associated with a
pregnancy loss rate of about 0.3 percent.25 This risk is
avoided with noninvasive methods to obtain fetal cells
or fetal cell-free DNA from the maternal circulation and
maternal blood has been used routinely for
determination of fetal RHD status in Europe.10,26 Fetal
DNA can be isolated from maternal plasma as early as
32 days’ gestation and constitutes 3 to 6 percent of the
plasma DNA pool in the second and third trimesters.10
Cell-free fetal DNA is rapidly cleared and does not
persist into subsequent pregnancies in contrast to the
potential for long-term persistence of fetal leukocytes
that can complicate analysis of cellular fetal DNA.27
Several groups have demonstrated 96 to 100 percent
accuracy in predicting the RhD phenotype with over
200 pregnancies tested.10,19,26 False positives were the
result of the presence of a pseudogene or D variant;
false negatives resulted from the failure to isolate
sufficient fetal DNA. When negative results are
obtained (e.g., no RhD-specific signal is detected), the
presence of fetal DNA in the plasma should be
confirmed by another fetus-specific DNA sequence
from a highly polymorphic paternal antigen or from
the Y chromosome for male fetuses (e.g., SRY). There
are no reported strategies for Kell testing or Rh testing
other than for RHD using a sample of maternal blood,
which likely reflects the difficulty of developing a
sensitive assay for subtle allelic differences that will still
be specific in the presence of an excess of maternal
DNA.10,26
Monitoring Affected Pregnancies
When a clinically significant antibody is detected in
a woman’s first pregnancy,maternal antibody titers are
typically determined each month until approximately
24 weeks’ gestation. Although the concept of a critical
titer has been challenged, most laboratories consider
the titer of anti-D that is associated with a significant
risk of severe HDF to be 32. Maternal antibody titers
are only useful in a first pregnancy, not in assessing
subsequent antigen-positive pregnancies. The utility of
antibody titers in monitoring Kell-sensitized
pregnancies is limited because the severity of
intrauterine disease may not correlate with maternal
antibody titers, and severe HDF has occurred with low
anti-K titers.2 Conversely, most other RBC antibodies
are less likely to cause severe disease than anti-D and
anti-K, and higher thresholds for antibody titers during
pregnancy have been used.7 Because the antibody titer
will depend on laboratory technique, there can be
considerable variability in titers when the same sample
is analyzed by different institutions; however, serial
assessment of titer by an individual institution should
reliably reflect trends when careful attention is given to
consistent and appropriate laboratory methods. For all
RBC antibodies implicated in HDF, a fourfold increase
in antibody titer is considered a significant change that
warrants further diagnostic investigation.
The most significant advance in monitoring
alloimmunized pregnancies has been the recent
demonstration that the severity of fetal anemia can
be predicted by a noninvasive method, Doppler
ultrasound, which obviates the need for serial amnio-
centesis to measure bilirubin concentration (∆OD450) in
most cases.28 In the presence of significant fetal
anemia, the velocity of blood flow through the middle
cerebral artery (MCA) increases and the change can
be detected by Doppler ultrasound. In a prospective
study of 165 fetuses with maternal RBC alloimmun-
ization (anti-D, -c, -E, or -Fya), an increase in peak
velocity in the MCA expressed as more than 1.5
multiples of the median (MoM) had a sensitivity of 88
percent and a specificity of 82 percent for severe fetal
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anemia.28 The performance of Doppler ultrasound was
better than that of amniocentesis using the Liley curve,
but similar to that of amniocentesis with Queenan’s
method. Doppler ultrasound has also been used to
manage Kell-sensitized pregnancies and is preferred to
amniocentesis which is often unreliable when HDF is
caused by anti-K because these antibodies not only
cause hemolysis but also suppress erythropoiesis as
reflected by falsely reassuring ∆OD450 values in the
setting of profound fetal anemia.29 Fetal blood
sampling to directly measure fetal hematologic
parameters is generally undertaken after Doppler MCA
ultrasound suggests the presence of severe or
worsening fetal anemia.
Intrauterine Transfusion for HDF
Prenatal monitoring of maternal antibody titers and
fetal MCA velocity with Doppler ultrasound may
indicate the need for fetal blood sampling and
intrauterine transfusion. If a woman with a rare null
phenotype has corresponding RBC antibodies, the
identification of antigen-negative blood for transfusion
is a major challenge facing the transfusion service.
Washed maternal RBCs are a potential source of
antigen-negative RBCs that can be collected and used
for intrauterine transfusion to the fetus. Blood
donation during pregnancy may risk premature labor
and fetal intrauterine growth restriction but is usually
well tolerated and must be weighed against the need
for antigen-negative blood for the fetus. Recently,ABO-
incompatible maternal blood was successfully used for
intrauterine transfusion when ABO-compatible RBCs
which lacked the implicated antigen were not
available.30 A pregnant woman with the rare
homozygous type D– (RH:-17), characterized by the
complete absence of C, c, E, and e antigens and the
elevated expression of D on the surface of RBCs,
demonstrated antibodies against the high-incidence
antigen Rh17. Her second infant was severely anemic
at birth, and a hydropic fetus was identified early in the
course of her third pregnancy.ABO-compatible, Rh17–
RBCs were not available; consequently, washed
maternal RBCs (group B) were used for seven
intrauterine transfusions to the group O fetus prior to
36 weeks’ gestation. At birth, the infant’s RBCs typed
group B, D+ and had a negative DAT with no evidence
of mixed field agglutination. A Kleihauer-Betke test on
cord blood indicated the presence of adult Hb and no
detectable fetal Hb. Phototherapy was initiated at birth
but was discontinued after the first day because the
indirect bilirubin was 55 µmol/L at birth and remained
stable,while the initial Hb (143 g/L) improved by day 3
(209 g/L). Exchange transfusion was not required; the
infant was reported to be healthy at 2 weeks of age
with no evidence of neurologic impairment. The case
demonstrates that ABO incompatibility is not a
deterrent to intrauterine transfusion of maternal blood
because anti-A and anti-B are not present during
gestation and are usually absent or only weakly
detectable at birth. ABO-mismatched transfusion is an
option for rare cases when antigen compatible or
group O RBCs cannot be obtained for intrauterine
transfusion. Maternal blood should be washed to
remove antibody, leukoreduced to lower the risk of
CMV transmission, and irradiated to prevent GVHD.
Evaluation of Infants at Risk for HDN
Immunohematologic testing of infants born to
women with potentially significant RBC antibodies
should include ABO and D typing as well as a DAT.13 If
HDN is suspected on clinical grounds, but the DAT and
maternal antibody screen are negative, the possibility
of incompatibility should be investigated by testing the
mother’s serum or an eluate prepared from the infant’s
RBCs against the biologic father’s RBCs. A negative
DAT does not rule out the possibility of immune-
mediated hemolytic anemia and may reflect a low-
antigen density on fetal RBCs or low avidity of the
offending antibody under the reaction conditions.1
However, when the infant’s DAT is negative, neonatal
hyperbilirubinemia should not be attributed to ABO
incompatibility; other possible causes of hemolysis
should be evaluated.31
Routine immunohematologic testing of infants
born to women with negative antibody screens is not
necessary, except to determine the need for RhIG for
D– women.13 Regardless,many institutions continue to
perform ABO and D typing and a DAT on all newborns;
others selectively test infants born to group O, D+
mothers. The latter strategy, which is intended to
identify infants at risk of developing ABO HDN, has an
extremely poor predictive value and is not
recommended because it will miss cases of hemolysis
resulting from nonimmune causes.13,32 In one study, the
positive predictive value of a routine cord DAT was
only 23 percent and the sensitivity only 86 percent.32
Functional assays that evaluate antibody-mediated RBC
destruction, such as the erythrophagocytosis assay,
may be useful adjuncts to predict the severity of HDN
but are technically demanding and suffer from
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limitations similar to those of the DAT.33 Instead of
reliance on laboratory screening for HDN or tests to
predict its course, all newborns should be followed for
jaundice in the first week of life with directed use of
serum bilirubin and other laboratory testing, as
appropriate.
Treatment of HDN
Hyperbilirubinemia does not occur before birth
because the bilirubin that results from the immune-
mediated destruction of fetal RBCs is transported
across the placenta and eliminated by the maternal
liver. After birth, however, serum bilirubin can
accumulate to dangerous levels with ongoing
hemolysis that poses a direct threat of brain damage
because the infant’s liver function is not fully
developed. Hyperbilirubinemia also occurs in
otherwise healthy infants, resulting in neonatal
jaundice which is the most common indication for
treatment in newborn infants.34 The degree and
duration of hyperbilirubinemia that place an infant at
risk for bilirubin encephalopathy and kernicterus have
been debated for years. Recently, a prospective,
blinded study compared 140 term and near-term
infants with total serum bilirubin levels of 25 mg/dL
(428 µmol/L) or more to 419 control subjects and
found no significant differences between the two
groups in neurodevelopmental outcomes.35 However,
the subgroup of infants with hyperbilirubinemia
resulting from immune-mediated hemolytic disease
had lower IQ scores than the control group. This
observation corroborates previous studies that
suggested that hemolysis enhances the risk of bilirubin-
induced central nervous system injury, although it is
not clear why. Factors potentiating bilirubin toxicity in
the setting of hemolytic disease may include acid-base
disturbances, asphyxia, free heme groups, and other
byproducts of hemolysis or drugs that displace
bilirubin from albumin and other plasma-binding
protein. The recent clinical practice guidelines from
the American Academy of Pediatrics treat infants with
jaundice caused by immune-mediated hemolysis more
aggressively than infants with physiologic jaundice, for
every given serum unconjugated bilirubin concen-
tration.34 Phototherapy is the mainstay of treatment for
neonatal jaundice, but exchange transfusion will be
necessary when phototherapy fails to adequately
decrease bilirubin concentration or when the initial
serum bilirubin concentration places the infant at high
risk for kernicterus. Treatment of jaundiced preterm
infants and jaundice on the first day of life in any infant
requires individualized treatment decisions. Treatment
decisions after the first 24 hours are guided by
gestational age, bilirubin concentration, and the rate of
its increase (> 0.5 mg/dL/hr), as well as the presence of
comorbid factors such as hemolysis, asphyxia,
significant lethargy, temperature instability, sepsis, or
acidosis.34 Immediate exchange transfusion is
recommended if an infant shows signs of acute
bilirubin encephalopathy (e.g., hypertonia, arching,
fever, high pitched cry) or if total serum bilirubin is 25
mg/dL (428 µmol/L) or more.34 Severe reactions
related to the procedure have been reported in about
5 percent of infants and include citrate-related
arrhythmias, bleeding caused by dilutional
coagulopathy or thrombocytopenia, catheter-related
infection, and bacterial sepsis.34 The mortality rate
among term infants within six hours of exchange
transfusion was estimated as 3 to 4 per 1000.34
Infants who respond to phototherapy alone or
those who receive intrauterine transfusion may not
require exchange transfusion. However, these infants
may need straight RBC transfusions (also referred to by
some clinicians as booster or top-off transfusions)
during the first 1 to 3 months of life for late-onset
anemia resulting from ongoing low-grade hemolysis or
erythropoietic suppression. In general, the transfusion
decision should be guided not only by the Hb
concentration but also by the reticulocyte count and,
most importantly, by the infant’s condition, particularly
when the infant is lethargic, feeding poorly, or not
thriving.
Conclusion
The advent of RhIG prophylaxis to prevent D
alloimmunization in pregnancy represents one of the
most significant medical advances in modern times,
reducing the risk of D alloimmunization from 14
percent in the late 1960s to 0.1 percent with the
routine use of antenatal and postpartum RhIG
administration.1–3 Further improvements in prenatal
care, noninvasive monitoring, and intrauterine
transfusion have provided effective treatment to even
the most severely affected infants with hydrops fetalis
caused by anti-D or other clinically significant,maternal
RBC antibodies.Women with RBCs of known partial D
phenotypes may be at significant risk of alloimmuni-
zation and may benefit from RhIG administration.
Noninvasive fetal diagnosis using maternal DNA is
possible for predicting the presence of RHD, although
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not yet routine in the United States. Doppler
ultrasound, now in widespread use, allows for
monitoring of affected pregnancies without the
potential complications associated with amniocentesis
or fetal blood sampling. Infants with hyperbilirubin-
emia associated with HDN are at greater risk of
neurologic complications than infants without
hemolysis, and the current practice guidelines from the
American Academy of Pediatrics identify HDN as a
significant risk factor that requires more aggressive
treatment at any given level of hyperbilirubinemia than
in the absence of hemolysis.
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